MacroGenics to Participate in Upcoming Investor Conference
MacroGenics, a biopharmaceutical company focused on antibody-based cancer therapeutics, will participate in the JMP Securities Life Sciences Conference on June 16, 2022, at 12:00 pm ET.
Rhea-AI Summary
MacroGenics, a biopharmaceutical company focused on antibody-based cancer therapeutics, will participate in the JMP Securities Life Sciences Conference on June 16, 2022, at 12:00 pm ET. The management will engage in a fireside chat and one-on-one meetings with investors. A webcast will be available on MacroGenics' website under the Investor Relations section, with an archived replay accessible for 30 days post-event. This participation highlights MacroGenics' commitment to advancing innovative cancer treatments through strategic collaborations and proprietary technology platforms.
Positive
- None.
Negative
- None.
Details
News Market Reaction – MGNX
The recorded move for MGNX in the trading session of this news was -7.25%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, MD, June 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference in June 2022:
- The JMP Securities Life Sciences Conference. MacroGenics’ management is scheduled to participate in a fireside chat on Thursday, June 16, 2022, at 12:00 pm ET, and will also participate in one-on-one meetings.
A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.